Protalix BioTherapeutics, Inc.: 10-Q filed 2014-11-10

Name: Protalix BioTherapeutics, Inc.: 10-Q filed 2014-11-10
Creator: Protalix BioTherapeutics, Inc.

What Protalix BioTherapeutics, Inc. reported in its quarterly report filed 2014-11-10 (fiscal Q3 2014): 21 published measures, 62 facts as tagged in accession 0001144204-14-066530.

This filing

Form: 10-Q (quarterly report)
Filed: 2014-11-10
Fiscal period: fiscal Q3 2014
Accession: 0001144204-14-066530 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Protalix BioTherapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-09-30	84,795,000	USD
At 2013-12-31	113,333,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-09-30	132,489,000	USD
At 2013-12-31	140,279,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2014-09-30	-47,694,000	USD
At 2013-12-31	-26,946,000	USD
At 2013-09-30	-16,706,000	USD
At 2012-12-31	-3,357,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-09-30	60,317,000	USD
At 2013-12-31	86,398,000	USD
At 2013-09-30	91,397,000	USD
At 2012-12-31	52,035,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	-8,010,000	USD	92
2014-01-01 to 2014-09-30	-21,474,000	USD	273
2013-07-01 to 2013-09-30	-5,747,000	USD	92
2013-01-01 to 2013-09-30	-16,905,000	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	617,000	USD	273
2013-01-01 to 2013-09-30	1,668,000	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	2,396,000	USD	92
2014-01-01 to 2014-09-30	11,517,000	USD	273
2013-07-01 to 2013-09-30	2,284,000	USD	92
2013-01-01 to 2013-09-30	8,116,000	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-09-30	11,846,000	USD
At 2013-12-31	13,711,000	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	683,000	USD	273
2013-01-01 to 2013-09-30	3,453,000	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	-6,208,000	USD	92
2014-01-01 to 2014-09-30	-18,123,000	USD	273
2013-07-01 to 2013-09-30	-5,645,000	USD	92
2013-01-01 to 2013-09-30	-16,968,000	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-09-30	71,208,000	USD
At 2013-12-31	97,903,000	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-09-30	24,384,000	USD
At 2013-12-31	26,696,000	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2014-09-30	1,992,000	USD
At 2013-12-31	2,091,000	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2014-09-30	6,830,000	USD
At 2013-12-31	7,957,000	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	1,909,000	USD	92
2014-01-01 to 2014-09-30	6,300,000	USD	273
2013-07-01 to 2013-09-30	1,772,000	USD	92
2013-01-01 to 2013-09-30	6,515,000	USD	273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	1,798,000	USD	92
2014-01-01 to 2014-09-30	7,476,000	USD	273
2013-07-01 to 2013-09-30	1,587,000	USD	92
2013-01-01 to 2013-09-30	3,876,000	USD	273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	2,012,000	USD	92
2014-01-01 to 2014-09-30	7,289,000	USD	273
2013-07-01 to 2013-09-30	1,780,000	USD	92
2013-01-01 to 2013-09-30	6,065,000	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	8,052,000	USD	92
2014-01-01 to 2014-09-30	23,280,000	USD	273
2013-07-01 to 2013-09-30	7,723,000	USD	92
2013-01-01 to 2013-09-30	23,467,000	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	-1,802,000	USD	92
2014-01-01 to 2014-09-30	-3,351,000	USD	273
2013-07-01 to 2013-09-30	-102,000	USD	92
2013-01-01 to 2013-09-30	63,000	USD	273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	578,000	USD	273
2013-01-01 to 2013-09-30	798,000	USD	273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	-1,127,000	USD	273
2013-01-01 to 2013-09-30	3,538,000	USD	273

Inspect the source

Entity: Protalix BioTherapeutics, Inc. / CIK 0001006281
Captured: 2026-09-20T05:12:00.706Z
SEC response SHA-256: 5022eb9c9008f3ac21090b4bd34c0341e843ccbd807493dfa2a9e5fc19632a16

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001006281.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))